AbbVie in Genmab Cancer Pact That Could Be Worth Over $3 Billion

(Bloomberg) -- AbbVie Inc. and Genmab A/S embarked on a broad cancer research and development pact that may bring the Danish biotechnology company payments of more than $3 billion.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.